Models of care and their cost-effectiveness in HCV treatment; the South Australian state-wide experience

Jeyamani Ramachandran, Billingsley Kaambwa, Kate Muller, James Haridy, Edmund Tse, Emma Tilley, Victoria Waddell, David Gordon, David Shaw, Dep Huynh, Jeffrey Stewart, Renjy Nelson, Morgyn Warner, Mark Boyd, Mohamed Asif Chinnaratha, Damian Harding, Lucy Ralton, Anton Colman, Richard Woodman, Alan J. Wigg

Research output: Contribution to journalMeeting Abstract

Abstract

Background: Providing unrestricted access to directly acting antiviral drugs (DAAs), Australia is committed to eradicating HCV. Innovations in models of care (MOC) and decentralization of HCV care to avoid limitations of specialist tertiary care models are two of the strategies used to augment treatment capacity.
Original languageEnglish
Article number976
Pages (from-to)569A
Number of pages1
JournalHepatology
Volume68
Issue numberS1
DOIs
Publication statusPublished - Oct 2018
EventLiver Meeting 2018: Annual Meeting of the American Association for the Study of Liver Diseases - San Francisco, United States
Duration: 9 Nov 201813 Nov 2018
https://liverlearning.aasld.org/the-liver-meeting-2018-content

Keywords

  • Models of care
  • HCV treatment
  • South Australia
  • Directly acting antiviral drugs

Fingerprint

Dive into the research topics of 'Models of care and their cost-effectiveness in HCV treatment; the South Australian state-wide experience'. Together they form a unique fingerprint.

Cite this